These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. Tolsma SS; Volpert OV; Good DJ; Frazier WA; Polverini PJ; Bouck N J Cell Biol; 1993 Jul; 122(2):497-511. PubMed ID: 7686555 [TBL] [Abstract][Full Text] [Related]
5. Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. Vogel T; Guo NH; Krutzsch HC; Blake DA; Hartman J; Mendelovitz S; Panet A; Roberts DD J Cell Biochem; 1993 Sep; 53(1):74-84. PubMed ID: 8227183 [TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid and bFGF control different modes in proliferating myoblasts. Yoshida S; Fujisawa-Sehara A; Taki T; Arai K; Nabeshima Y J Cell Biol; 1996 Jan; 132(1-2):181-93. PubMed ID: 8567722 [TBL] [Abstract][Full Text] [Related]
8. Metabolism of thrombospondin 2. Binding and degradation by 3t3 cells and glycosaminoglycan-variant Chinese hamster ovary cells. Chen H; Strickland DK; Mosher DF J Biol Chem; 1996 Jul; 271(27):15993-9. PubMed ID: 8663244 [TBL] [Abstract][Full Text] [Related]
20. Possible mechanism for lead inhibition of vascular endothelial cell proliferation: a lower response to basic fibroblast growth factor through inhibition of heparan sulfate synthesis. Fujiwara Y; Kaji T Toxicology; 1999 Apr; 133(2-3):147-57. PubMed ID: 10378481 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]